News Sentiment

CMPX sentiment intelligence

Compass Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.33 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.6% over one week, +14.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 2.6% Price confirming higher
Trend fit Trend inactive 14.8% over four weeks
Fair value -11.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 35
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 9
TradingKey 6
Insider Monkey 5
GlobeNewswire 4
The Globe and Mail 3
Stock Titan 3
The National Law Review 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 19
Analyst action 6
Regulatory and legal 3
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Quartr Direct company coverage

Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Compass Therapeutics presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting progress on four clinical-stage oncology drugs. The lead asset, tovecimig, is advancing toward potential FDA BLA filing and showed significant efficacy in a phase II/III BTC

Tone
Positive 75/100
Event
Market update
Published
08 Jul 2026 13:40
Source
Quartr
Stocktwits Direct company coverage

CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update

Compass Therapeutics (CMPX), a biotech company, is generating significant retail investor interest ahead of its Phase 2/3 trial data release for its cancer drug Tovecimig, used to treat advanced biliary tract cancer. The drug, in combination with Paclitaxel, has shown promising e

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:11
Source
Stocktwits
Stock Titan Direct company coverage

If You Invested $1,000 in Compass Therapeutics Inc (CMPX)

This article analyzes the historical performance of investing $1,000 in Compass Therapeutics Inc (CMPX) over different periods, detailing the current worth of such an investment and its annual returns. It also provides a comprehensive overview of Compass Therapeutics, a clinical-

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 00:40
Source
Stock Titan
Insider Monkey Direct company coverage

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)

Citizens has reiterated a Market Outperform rating on Compass Therapeutics (CMPX) with a $10 price target after the company presented promising clinical data at the ASCO conference for its bispecific antibody, CTX-8371. This drug showed early signs of activity in treating difficu

Tone
Positive 75/100
Event
Analyst action
Published
03 Jul 2026 13:39
Source
Insider Monkey
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026 announcement regarding a phase 2/3 study for its drug tovecimig, which, d

Tone
Negative 18/100
Event
Regulatory and legal
Published
02 Jul 2026 06:09
Source
The National Law Review
TradingView Direct company coverage

Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement

Compass Therapeutics (`CMPX`) has updated its corporate presentation, revealing positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer (BTC). The data shows improved objective response rate (ORR) and progression-free survival (PFS) for a combinati

Tone
Positive 82/100
Event
Market update
Published
01 Jul 2026 20:39
Source
TradingView
Stock Titan Direct company coverage

Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success

Compass Therapeutics' tovecimig, in combination with paclitaxel, showed significant improvement in overall response rate (18.0% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months) in a Phase 2/3 trial for second-line biliary tract cancer. The company plans an FDA

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 20:39
Source
Stock Titan
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which met a key second

Tone
Negative 8/100
Event
Earnings
Published
01 Jul 2026 19:41
Source
The National Law Review
TradingView Direct company coverage

Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX

This article focuses on the "Price to earnings forward" financial metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). While the article title presents this topic, there is no actual data or discussion provided within the content. The body of the article appears to be primarily

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 01:12
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX

This page displays the "Price to sales forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX) as provided by TradingView. The content primarily focuses on financial data for the company within the Pharmaceuticals: Major sector and indicates market closure with no current t

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX

This article focuses on the "Enterprise value to revenue forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). The content is primarily a header with navigation and footer details, indicating a financial data point for the company on the TradingView platform.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 16:41
Source
TradingView
www.marketscreener.com Direct company coverage

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark

Compass Therapeutics, Inc. (NasdaqCM:CMPX), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has been dropped from the Russell 3000E Growth Benchmark. The company's stock shows a 5-day change of +0.48% and a year-to-date change of -61.27%. Compass Ther

Tone
Negative 29/100
Event
Market update
Published
29 Jun 2026 05:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark

Compass Therapeutics, Inc. (NasdaqCM:CMPX) has been removed from several Russell benchmarks, including the Russell Small Cap Comp Growth Benchmark, Russell 3000 Growth Benchmark, and Russell Microcap Growth Benchmark Index. This news follows a recent downgrade by Raymond James an

Tone
Negative 38/100
Event
Analyst action
Published
28 Jun 2026 22:10
Source
marketscreener.com
TradingView Direct company coverage

Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX)

This article provides an overview of Compass Therapeutics, Inc. (NASDAQ:CMPX) stock data, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, discusses upcoming earnings reports, and provides a

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

CMPX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Compass Therapeutics, Inc. (CMPX) stock for 2027 based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, and key financial information like recent earnings, revenue, and

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:42
Source
TradingView
TradingKey Direct company coverage

Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Compass Therapeutics Inc. (CMPX), highlighting its current valuation score, market capitalization, and P/E ratio. As of June 26, 2026, the company's valuation score is 8.69, ranking 104 out of 387 in the Biotechnology & Medical Resea

Tone
Negative 39/100
Event
Market update
Published
24 Jun 2026 08:10
Source
TradingKey
Moomoo Direct company coverage

Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Compass Therapeutics (CMPX). It serves as a resource for investors looking for insights into the company's financial prospects and market sentiment.

Tone
Neutral 50/100
Event
Guidance
Published
23 Jun 2026 13:09
Source
Moomoo
TradingKey Direct company coverage

Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), noting that essential financial data such as business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It only shows a placeholder for "United States" wi

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:39
Source
TradingKey
Insider Monkey Direct company coverage

How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing

Compass Therapeutics (CMPX) is advancing its experimental cancer treatment, tovecimig, for biliary tract cancer, having received FDA Orphan Drug Designation and planning an approval application later in 2026. The company reported strong tumor response in late-stage studies and ha

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jun 2026 11:16
Source
Insider Monkey
TradingKey Direct company coverage

Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Compass Therapeutics Inc. (CMPX), highlighting its current earnings forecast score of 8.67 and ranking within the Biotechnology & Medical Research industry. It details analyst ratings, revealing a strong "Buy" consensus with an avera

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 08:11
Source
TradingKey
TradingKey Direct company coverage

Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Compass Therapeutics Inc. (CMPX) financial health, highlighting its current financial score of 6.36, which ranks it 257 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is considered robust, its

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 08:11
Source
TradingKey
TradingKey Direct company coverage

Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its current price momentum score, support and resistance levels, and indicator readings (MACD, RSI, KDJ, etc.) and moving averages. According to the analysis, CMPX currently has a price mome

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 08:11
Source
TradingKey
Insider Monkey Direct company coverage

5 Small Cap Stocks with Potential to Rise 1000 Percent

This article highlights Compass Therapeutics, Inc. (NASDAQ: CMPX) as a small-cap stock with significant growth potential, possibly rising 1000 percent. The company is developing tovecimig, an experimental cancer treatment that recently received FDA Orphan Drug Designation and sho

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 13:10
Source
Insider Monkey
The Globe and Mail Direct company coverage

Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight

Compass Therapeutics, Inc. shareholders recently re-elected two Class III directors, Thomas J. Schuetz and Richard S. Lindahl, and ratified CohnReznick, LLP as their independent auditor. Investors also approved the compensation for executive officers and supported an annual advis

Tone
Negative 40/100
Event
Market update
Published
14 Jun 2026 05:40
Source
The Globe and Mail
www.marketscreener.com Direct company coverage

Transcript : Compass Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08

This article is a transcript of Compass Therapeutics, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026. The presentation started at 8:00 AM. The full article content is reserved for subscribers.

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 17:40
Source
www.marketscreener.com
Stock Titan Direct company coverage

Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes

Compass Therapeutics, Inc. stockholders approved all proposals at their annual meeting on June 10, 2026. This included re-electing Class III directors Thomas J. Schuetz and Richard S. Lindahl, ratifying CohnReznick LLP as the independent auditor, and approving executive compensat

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 15:09
Source
Stock Titan